Author Correction: PAK4 inhibition improves PD-1 blockade immunotherapy - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Correction: PAK4 inhibition enhances the efficacy of PD-1 blockade immunotherapy

  • By

  • Gabriel Abril-Rodriguez

  • Davis Y. Torrejon

  • Wei Liu

  • Jesse M. Zaretsky

  • Theodore S. Nowicki

  • Jennifer Tsoi

  • Cristina Puig-Saus

  • Ignacio Baselga-Carretero

  • Egmidio Medina

  • Michael J. Quist

  • Alejandro J. Garcia

  • William Senapedis

  • Erkan Baloglu

  • Anusha Kalbasi

  • Gardenia Cheung-Lau

  • Beata Berent-Maoz

  • Begoña Comin-Anduix

  • Siwen Hu-Lieskovan

  • Cun-Yu Wang

  • Catherine S. Grasso

  • Antoni Ribas

  • October 9, 2026

Share

Objective:

The article examines the objective, findings, and clinical context described in Correction: PAK4 inhibition enhances the efficacy of PD-1 blockade immunotherapy.

Approach:
  • Correction: The Fig. 5 legend and associated source data file were amended to identify the experiments contributing to the reported mouse counts.
Key Findings:
  • The n = 16 mice shown for each group in Fig. 5a were pooled across three independent experiments.
  • Fig. 5d showed one experiment with n = 6 mice in each of the PAK4 KO isotype and PAK4 KO anti-PD1 groups, and n = 5 in the PAK4 KO anti-PD1 anti-CD8 group.
  • The correction was incorporated into the HTML and PDF versions of the article.
Interpretation:

The correction clarifies how the Fig. 5 sample counts relate to the experiments.

Sources:

Original Source(s)

Related Content